Euroasian journal of hepato-gastroenterology

Register      Login

VOLUME 9 , ISSUE 2 ( July-December, 2019 ) > List of Articles


Update on Immunosuppression in Liver Transplantation

Burcak E Tasdogan, Michelle Ma, Cem Simsek, Behnam Saberi, Ahmet Gurakar

Keywords : Adverse effects, Immunosuppression, Liver transplantation

Citation Information : Tasdogan BE, Ma M, Simsek C, Saberi B, Gurakar A. Update on Immunosuppression in Liver Transplantation. Euroasian J Hepatogastroenterol 2019; 9 (2):96-101.

DOI: 10.5005/jp-journals-10018-1301

License: CC BY-NC 4.0

Published Online: 01-08-2017

Copyright Statement:  Copyright © 2019; The Author(s).


The standard therapy for decompensated end-stage chronic liver disease of any etiology and acute fulminant hepatic failure is liver transplantation (LT). Advances in immunosuppressive therapy decreased the rates of acute and chronic rejections. Thus, graft and patient survivals have significantly improved. However, long-term adverse effects of prolonged use of immunosuppressive agents such as malignancies, opportunistic infections, metabolic disorders, and other organ toxicities have now become a major concern. Consequently, alternative approaches are needed to deescalate the customary drugs and their side effects. Therapy must be individualized and additional preventive measures should be taken by patients with particular risk factors or predisposed to certain adverse effects. Current opinion favors a combination of agents with different mechanism of actions and toxicity profiles. Corticosteroids are employed in immediate and early postoperative period. Although they have a pronounced side effect profile, calcineurin inhibitors (CNIs) are still the backbone of early and late phase immunosuppressive regimens because of their proved efficacy. Antimetabolites are frequent choices for steroid and/or CNI-sparing strategies. Studies also have established a role for mammalian target of rapamycin (mTOR) inhibitors in specific groups of recipients. Biologic agents are a hot topic of interest and made their way into current strategies for induction. Agents extrapolated from other transplantation or immunologic experience are being evaluated.

  1. Starzl TE, Iwatsuki S, Van Thiel DH, et al. Evolution of liver transplantation. Hepatology 1982;2(5):614–636. DOI: 10.1002/hep.1840020516.
  2. Shukla A, Vadeyar H, Rela M, et al. Liver transplantation: east versus west. J Clin Exp Hepatol 2013;3(3):243–253. DOI: 10.1016/j.jceh.2013.08.004.
  3. Rana A, Ackah RL, Webb GJ, et al. No gains in long-term survival after liver transplantation over the past three decades. Ann Surg 2018;269(1):20–27. DOI: 10.1097/SLA.0000000000002650.
  4. Åberg F, Gissler M, Karlsen TH, et al. Differences in long-term survival among liver transplant recipients and the general population: a population-based nordic study. Hepatology 2015;61(2):668–677. DOI: 10.1002/hep.27538.
  5. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003;349(10):931–940. DOI: 10.1056/NEJMoa021744.
  6. Wiesner RH, Fung JJ. Present state of immunosuppressive therapy in liver transplant recipients. Liver Transpl 2011;17(Suppl 3):S1–S9. DOI: 10.1002/lt.22410.
  7. De Simone P, Carrai P, Coletti L, et al. Modification of immunosuppressive therapy as risk factor for complications after liver transplantation. Best Pract Res Clin Gastroenterol 2017;31(2):199–209. DOI: 10.1016/j.bpg.2017.03.001.
  8. Burra P, Burroughs A, Forns X, et al. EASL clinical practice guidelines: liver transplantation. J Hepatol 2016;64(2):433–485. DOI: 10.1016/j.jhep.2015.10.006.
  9. Levitsky J, Goldberg D, Smith AR, et al. Acute rejection increases risk of graft failure and death in recent liver transplant recipients. Clin Gastroenterol Hepatol 2017;15(4):584.e2–593.e2. DOI: 10.1016/j.cgh.2016.07.035.
  10. Fussner LA, Heimbach JK, Fan C, et al. Cardiovascular disease after liver transplantation: when, what, and who is at risk. Liver Transpl 2015;21(7):889–896. DOI: 10.1002/lt.24137.
  11. Masuda S, Inui K-i. An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol Ther 2006;112(1):184–198. DOI: 10.1016/j.pharmthera.2006.04.006.
  12. Charlton M, Levitsky J, Aqel B, et al. International liver transplantation society consensus statement on immunosuppression in liver transplant recipients. Transplantation 2018;102(5):727–743. DOI: 10.1097/TP.0000000000002147.
  13. McAlister VC, Haddad E, Renouf E, et al. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant 2006;6(7):1578–1585. DOI: 10.1111/j.1600-6143.2006.01360.x.
  14. Busuttil RW, Farmer DG, Yersiz H, et al. Analysis of long-term outcomes of 3200 liver transplantations over two decades: a single-center experience. Ann Surg 2005;241(6):905–916. DOI: 10.1097/01.sla.0000164077.77912.98.
  15. Jain A, Singhal A, Fontes P, et al. One thousand consecutive primary liver transplants under tacrolimus immunosuppression: a 17-to 20-year longitudinal follow-up. Transplantation 2011;91(9):1025–1030. DOI: 10.1097/ICO.0000000000001267.
  16. Beckebaum S, Iacob S, Sweid D, et al. Efficacy, safety, and immunosuppressant adherence in stable liver transplant patients converted from a twice-daily tacrolimus-based regimen to once-daily tacrolimus extended-release formulation. Transpl Int 2011;24(7): 666–675. DOI: 10.1111/j.1432-2277.2011.01254.x.
  17. Okumura Y, Noda T, Eguchi H, et al. Short-and long-term outcomes of de novo liver transplant patients treated with once-daily prolonged-release tacrolimus. Transpl Direct 2017;3(9):e207. DOI: 10.1097/TXD.0000000000000722.
  18. Knight SR, Morris PJ. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation 2008;85(12):1675–1685. DOI: 10.1097/TP.0b013e3181744199.
  19. Sterneck M, Fischer L, Gahlemann C, et al. Mycophenolate mofetil for prevention of liver allograft rejection: initial results of a controlled clinical trial. Ann Transplant 2000;5(1):43–46.
  20. Boudjema K, Camus C, Saliba F, et al. Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. Am J Transplant 2011;11(5): 965–976. DOI: 10.1111/j.1600-6143.2011.03486.x.
  21. D'avola D, Cuervas-Mons V, Martí J, et al. Cardiovascular morbidity and mortality after liver transplantation: the protective role of mycophenolate mofetil. Liver Transplant 2017;23(4):498–509. DOI: 10.1002/lt.24738.
  22. Doria C, Ramirez CB, Frank AM, et al. Use of enteric-coated mycophenolate sodium in liver transplant patients with intestinal intolerance caused by mycophenolate mofetil. Clin Transplant 2009;23(6):882–886. DOI: 10.1111/j.1399-0012.2009.01019.x.
  23. Kawahara T, Asthana S, Kneteman NM. m-TOR inhibitors: what role in liver transplantation? J Hepatol 2011;55(6):1441–1451. DOI: 10.1016/j.jhep.2011.06.015.
  24. Patel JK, Kobashigawa JA. Everolimus: an immunosuppressive agent in transplantation. Expert Opin Pharmacother 2006;7(10):1347–1355. DOI: 10.1517/14656566.7.10.1347.
  25. Monaco AP. The role of mTOR inhibitors in the management of posttransplant malignancy. Transplantation 2009;87(2):157–163. DOI: 10.1097/TP.0b013e318193886e.
  26. Neuhaus P, Klupp J, Langrehr JM. mTOR inhibitors: an overview. Liver Transplant 2001;7(6):473–484. DOI: 10.1053/jlts.2001.24645.
  27. Yee M-L, Tan H-H. Use of everolimus in liver transplantation. World J Hepatol 2017;9(23):990–1000. DOI: 10.4254/wjh.v9.i23.990.
  28. Montalbano M, Neff GW, Yamashiki N, et al. A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications. Transplantation 2004;78(2):264–268. DOI: 10.1097/
  29. Massoud O, Wiesner RH. The use of sirolimus should be restricted in liver transplantation. J Hepatol 2012;56(1):288–290. DOI: 10.1016/j.jhep.2011.06.012.
  30. Fischer L, Klempnauer J, Beckebaum S, et al. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation—PROTECT. Am J Transplant 2012;12(7):1855–1865. DOI: 10.1111/j.1600-6143.2012.04049.x.
  31. Maluccio M, Sharma V, Lagman M, et al. Tacrolimus enhances transforming growth factor-β1 expression and promotes tumor progression. Transplantation 2003;76(3):597–602. DOI: 10.1097/01.TP.0000081399.75231.3B.
  32. Schumacher G, Oidtmann M, Rosewicz S, et al. Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth. Transplant Proc 2002;34(5):1392–1393. DOI: 10.1016/s0041-1345(02)02899-3.
  33. Menon KV, Hakeem AR, Heaton ND. Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther 2013;37(4): 411–419. DOI: 10.1111/apt.12185.
  34. Geissler EK, Schnitzbauer AA, Zulke C, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial. Transplantation 2016;100(1): 116–125. DOI: 10.1097/TP.0000000000000965.
  35. Thorat A, Jeng LB, Yang HR, et al. Assessing the role of everolimus in reducing hepatocellular carcinoma recurrence after living donor liver transplantation for patients within the UCSF criteria: re-inventing the role of mammalian target of rapamycin inhibitors. Ann Hepatobiliary Pancreat Surg 2017;21(4):205–211. DOI: 10.14701/ahbps.2017.21.4.205.
  36. Teperman L, Moonka D, Sebastian A, et al. Calcineurin inhibitor–free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial. Liver Transplant 2013;19(7):675–689. DOI: 10.1002/lt.23658.
  37. Saliba F, De Simone P, Nevens F, et al. Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. Am J Transplant 2013;13(7):1734–1745. DOI: 10.1111/ajt.12280.
  38. De Simone P, Nevens F, De Carlis L, et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant 2012;12(11):3008–3020. DOI: 10.1111/j.1600-6143.2012.04212.x.
  39. Fischer L, Saliba F, Kaiser GM, et al. Three-year outcomes in de novo liver transplant patients receiving everolimus with reduced tacrolimus: follow-up results from a randomized, multicenter study. Transplantation 2015;99(7):1455–1462. DOI: 10.1097/TP.0000000000000555.
  40. De Simone P, Metselaar HJ, Fischer L, et al. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. Liver Transplant 2009;15(10):1262–1269. DOI: 10.1002/lt.21827.
  41. Sterneck M, Kaiser GM, Heyne N, et al. Long-term follow-up of five yr shows superior renal function with everolimus plus early calcineurin inhibitor withdrawal in the PROTECT randomized liver transplantation study. Clin Transplant 2016;30(6):741–748. DOI: 10.1111/ctr.12744.
  42. Sterneck M, Kaiser G, Heyne N, et al. Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation. Am J Transplant 2014;14(3):701–710. DOI: 10.1111/ajt.12615.
  43. Genestier L, Fournel S, Flacher M, et al. Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins. Blood 1998;91(7):2360–2368.
  44. Bamoulid J, Staeck O, Crepin T, et al. Anti-thymocyte globulins in kidney transplantation: focus on current indications and long-term immunological side effects. Nephrol Dial Transplant 2017;32(10): 1601–1608. DOI: 10.1093/ndt/gfw368.
  45. Bafloka I, Hsaiky L, Brown K, et al. Preserving renal function in liver transplant recipients with rabbit anti-thymocyte globulin and delayed initiation of calcineurin inhibitors. Liver Transplant 2008;14(1):66–72. DOI: 10.1002/lt.21309.
  46. Benitez C, Puig-Pey I, Lopez M, et al. ATG-fresenius treatment and low-dose tacrolimus: results of a randomized controlled trial in liver transplantation. Am J Transplant 2010;10(10):2296–2304. DOI: 10.1111/j.1600-6143.2010.03164.x.
  47. Goralczyk AD, Hauke N, Bari N, et al. Interleukin 2 receptor antagonists for liver transplant recipients: a systematic review and meta-analysis of controlled studies. Hepatology 2011;54(2):541–554. DOI: 10.1002/hep.24385.
  48. Neuhaus P, Clavien PA, Kittur D, et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transplant 2002;8(2):132–142. DOI: 10.1053/jlts.2002. 30302.
  49. Verna EC, Farrand ED, Elnaggar AS, et al. Basiliximab induction and delayed calcineurin inhibitor initiation in liver transplant recipients with renal insufficiency. Transplantation 2011;91(11):1254–1260. DOI: 10.1097/TP.0b013e318218f0f5.
  50. De Ataide EC, Perales SR, Bortoto JB, et al. Immunomodulation, acute renal failure, and complications of basiliximab use after liver transplantation: analysis of 114 patients and literature review. Transplant Proc 2017;49(4):852–857. DOI: 10.1016/j.transproceed.2017.01.047.
  51. Vincenti F. Are calcineurin inhibitors-free regimens ready for prime time? Kidney Int 2012;82(10):1054–1060. DOI: 10.1038/ki. 2012.194.
  52. Klintmalm GB, Feng S, Lake JR, et al. Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. Am J Transplant 2014;14(8):1817–1827. DOI: 10.1111/ajt.12810.
  53. Morris PJ, Russell NK. Alemtuzumab (Campath-1H): a systematic review in organ transplantation. Transplantation 2006;81(10): 1361–1367. DOI: 10.1097/
  54. Tzakis AG, Tryphonopoulos P, Kato T, et al. Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation. Transplantation 2004;77(8):1209–1214. DOI: 10.1097/
  55. Levitsky J, Thudi K, Ison MG, et al. Alemtuzumab induction in non-hepatitis C positive liver transplant recipients. Liver Transplant 2011;17(1):32–37. DOI: 10.1002/lt.22180.
  56. Alcaide ML, Abbo L, Pano JR, et al. Herpes zoster infection after liver transplantation in patients receiving induction therapy with alemtuzumab. Clin Transplant 2008;22(4):502–507. DOI: 10.1111/j.1399-0012.2008.00816.x.
  57. Marcos A, Eghtesad B, Fung JJ, et al. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation 2004;78(7):966–971. DOI: 10.1097/
  58. Madariaga MLL, Kreisel D, Madsen JC. Organ-specific differences in achieving tolerance. Curr Opin Organ Transplant 2015;20(4):392–399. DOI: 10.1097/MOT.0000000000000206.
  59. Knechtle SJ, Kwun J. Unique aspects of rejection and tolerance in liver transplantation. Semin Liver Dis 2009;29(1):91–101. DOI: 10.1055/s-0029-1192058.
  60. Benítez C, Londoño MC, Miquel R, et al. Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology 2013;58(5):1824–1835. DOI: 10.1002/hep.26426.
  61. Hussaini T, Turgeon RD, Partovi N, et al. Immunosuppression practices in liver transplantation: a survey of North American Centers. Exp Clin Transplant 2018;16(5):550–553. DOI: 10.6002/ect.2017.0096.
  62. Busuttil RW, McDiarmid S, Klintmalm GB, et al. U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. New Engl J Med 1994;331(17):1110–1115. DOI: 10.1056/NEJM199410273311702.
  63. Schlitt HJ, Barkmann A, Boker KHW, et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet 2001;357(9256):587–591. DOI: 10.1016/s0140-6736(00)04055-1.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.